Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The recent advancements that have been made ...
New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results